Stipple Bio raised $100 million in a Series A to advance STP-100, an antibody-drug conjugate (ADC) targeting an undisclosed antigen, and to expand its Pointillist discovery platform for precision cancer targets. The company emerged with a lead program positioned for progression into clinical testing in the near term. Stipple’s approach centers on identifying epitopes and cancer-specific features that may be less straightforward than classical overexpressed targets—using protein conformation and post-translational modification cues to differentiate tumor from healthy tissue. The financing adds to a crowded but still fertile ADC funding landscape, where investors are increasingly selective about target novelty and platform defensibility.